World Library  
Flag as Inappropriate
Email this Article

CDK inhibitor

Article Id: WHEBN0025397709
Reproduction Date:

Title: CDK inhibitor  
Author: World Heritage Encyclopedia
Language: English
Subject: Cyclin-dependent kinase, Melanoma, Restriction point, Targeted therapy
Publisher: World Heritage Encyclopedia

CDK inhibitor

This article is about the medical therapy. For the cell cycle protein, see Cyclin-dependent kinase inhibitor protein.

A CDK (Cyclin-dependent kinase) inhibitor is a chemical that inhibits the function of CDKs. It is used to treat cancers by preventing overproliferation of cancer cells. Although there is no approved anti-cancer drugs that target CDKs yet, several compounds are on clinical trials now (2009).

CDKs as cancer target

In many human cancers, CDKs are overactive or CDK-inhibiting proteins are not functional.[1][2] Therefore, it is rational to target CDK function to prevent unregulated proliferation of cancer cells.

However, the validity of CDK as a cancer target should be carefully assessed because genetic studies have revealed that knockout of one specific type of CDK often does not affect proliferation of cells or has an effect only in specific tissue types. For example, most adult cells in mice proliferate normally even without both CDK4 and CDK2.[3]

Furthermore, specific CDKs are only active in certain periods of the cell cycle. Therefore, the pharmacokinetics and dosing schedule of the candidate compound must be carefully evaulated to maintain active concentration of the drug throughout the entire cell cycle.[4]

Types of CDK inhibitors

Malumbres et al., categorized CDK inhibitors based on their target specificity;

  • Broad CDK inhibitors¬†; compounds targeting a broad spectrum of CDKs
  • Specific CDK inhibitors¬†; compounds targeting a specific type of CDK
  • Multiple target inhibitors¬†; compounds targeting CDKs as well as additional kinases such as VEGFR or PDGFR

CDK inhibitors on clinical trials

There are more than 10 CDK inhibitor compounds that have gone through or currently ongoing clinical trials, as of 2009. Most of them are targeting multiple CDKs, but some are targeting specific CDKs. For example, P1446A-05 targets CDK4 and PD-0332991 targets CDK4 and CDK6. All compounds are (as of 2009) either in phase I or phase II trials. Various types of cancers including
PD-0332991 gave encouraging results in a phase II clinical trial on patients with estrogen-positive, HER2-negative advanced breast cancer.[6] The addition of PD-0332991 to letrozole trebled median time to disease progression to 26.1 months compared with 7.5 months for letrozole alone.


de:CDK-Inhibitor 2A
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.